Assertio Therapeutics (ASRT) Tops Q1 EPS by 5c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $59.7 million versus the consensus estimate of $55.28 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c